TD Asset Management Inc Has $25.21 Million Holdings in Tenet Healthcare Corporation $THC

TD Asset Management Inc raised its holdings in Tenet Healthcare Corporation (NYSE:THC) by 4.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 126,882 shares of the company’s stock after buying an additional 5,130 shares during the period. TD Asset Management Inc owned about 0.14% of Tenet Healthcare worth $25,214,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in THC. Triumph Capital Management bought a new stake in Tenet Healthcare in the 3rd quarter valued at $25,000. Activest Wealth Management acquired a new position in shares of Tenet Healthcare in the fourth quarter valued at $26,000. Elyxium Wealth LLC bought a new position in shares of Tenet Healthcare in the fourth quarter valued at about $29,000. Canada Pension Plan Investment Board bought a new stake in shares of Tenet Healthcare during the 2nd quarter worth about $35,000. Finally, Geneos Wealth Management Inc. grew its stake in Tenet Healthcare by 50.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock valued at $46,000 after buying an additional 89 shares during the last quarter. 95.44% of the stock is owned by institutional investors and hedge funds.

Tenet Healthcare Stock Up 0.1%

NYSE THC opened at $162.20 on Monday. The company has a market cap of $13.97 billion, a price-to-earnings ratio of 8.43, a PEG ratio of 1.33 and a beta of 1.28. Tenet Healthcare Corporation has a 1-year low of $146.60 and a 1-year high of $247.21. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96. The company has a 50 day moving average of $186.17 and a 200-day moving average of $200.80.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings data on Thursday, April 30th. The company reported $4.82 EPS for the quarter, topping analysts’ consensus estimates of $4.21 by $0.61. The firm had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.39 billion. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, equities research analysts expect that Tenet Healthcare Corporation will post 17.61 earnings per share for the current fiscal year.

Insider Activity at Tenet Healthcare

In related news, Director Nadja West sold 3,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the sale, the director owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This represents a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paola M. Arbour sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the completion of the transaction, the executive vice president directly owned 29,291 shares in the company, valued at approximately $6,983,853.13. This represents a 18.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,138 shares of company stock valued at $3,065,789 over the last quarter. 0.97% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on THC. KeyCorp cut their price objective on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Jefferies Financial Group increased their target price on Tenet Healthcare from $250.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Barclays reduced their price target on Tenet Healthcare from $257.00 to $238.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Robert W. Baird lowered their price objective on Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Finally, Guggenheim reduced their target price on shares of Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Eighteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Tenet Healthcare has an average rating of “Moderate Buy” and an average target price of $244.16.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.